About the Company
a career at macrogenics could be waiting for you! please click on "careers" ---------------------------->>> to learn more. macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. macrogenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. the combination of macrogenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. these are exciting times at macrogenics and we hope that you will take the opportunity to learn more about our organization, our pipeline and to view our job opportunities!
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MGNX News
MacroGenics, Inc. (NASDAQ:MGNX) Q4 2023 Earnings Call Transcript
March 7, 2024 MacroGenics, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter ...
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
Presentation of preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024Initiation ...
Macrogenics Inc (MGNX) Reports Strong Financial Position and Advancements in Cancer Treatment ...
Shares Outstanding: As of December 31, 2023, there were 62,070,627 shares of common stock outstanding.
Analyst Expectations For Macrogenics's Future
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $18.0, a high ...
Maintaining Market Outperform for MacroGenics with Increased Confidence in ADC Leadership and Clinical Prospects
Analyst Silvan Tuerkcan of JMP Securities maintained a Buy rating on MacroGenics (MGNX – Research Report), with a price target of $22.00.
AbbVie ends stay with the ADAM family, dropping MacroGenics-partnered ADC in light of early data
AbbVie has cut short its call on the ADAM family. The ADAM9-targeted antibody-drug conjugate MGC936 fell short of safety and ...
Macrogenics Inc (NASDAQ: MGNX) Rise 4.02%, Now What? Don’t Panic
MGNX’s current price about 20.46% and 52.43% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 78.42, while 7-day volatility ratio ...
Insider Sell: COO Eric Risser Sells 41,159 Shares of Macrogenics Inc (MGNX)
Eric Risser, the Chief Operating Officer of Macrogenics Inc (NASDAQ:MGNX), has sold 41,159 shares of the company on March 4, ...
AMD To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...
Stocks Rise Before the Open as Investors Await U.S. Economic Data and Powell’s Testimony, ECB Decision in Focus
Mini futures (ESH24)are up +0.17%, and March Nasdaq 100 E-Mini futures (NQH24) are up +0.22% this morning as investors looked ahead to further testimony from Federal Reserve Chair Jerome Powell while ...
MacroGenics, Inc.: MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
4:30 p.m. ET ROCKVILLE, Md., March 07, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing ...
Stocks Climb Before the Open as Investors Await U.S. Economic Data and Powell’s Testimony, ECB Decision in Focus
Real-time index price for S&P 500 Index (INX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...
Loading the latest forecasts...